Enhanced expression of Organic Cation Transporters in bronchial epithelial cell layers following insults associated with asthma – impact on salbutamol transport by Mukherjee, Manali et al.
1Enhanced Expression of Organic Cation Transporters in Bronchial
Epithelial Cell Layers following Insults Associated with Asthma – Impact
on Salbutamol Transport
M. Mukherjee#, E.Cingolani, D.I. Pritchard and C. Bosquillon*
School of Pharmacy, University of Nottingham, University Park, Nottingham NG7
2RD, United Kingdom.
#Current address: Firestone Institute for Respiratory Health, McMaster University, Hamilton,
Ontario, Canada
* Correspondence to: Dr.Cynthia Bosquillon, School of Pharmacy, Boots Science Building,
University of Nottingham, University Park, Nottingham NG7 2RD, United Kingdom,
Telephone: +44 (0) 115 8466078, Fax: +44 (0) 115 9515122, e-mail:
cynthia.bosquillon@nottingham.ac.uk
2Abstract
Increasing evidence suggests Organic Cation Transporters (OCT) might facilitate the
absorption of inhaled bronchodilators, including salbutamol, across the lung epithelium. This
is essentially scarred and inflamed in asthma. Accordingly, the impact of epithelial insults
relevant to asthma on OCT expression and salbutamol transport was evaluated in air-liquid
interfaced layers of the human broncho-epithelial cell line Calu-3. These were physically
injured and allowed to recover for 48h or exposed to the pro-inflammatory stimulant
lipopolysaccharide (LPS) for 48h and the aeroallergen house dust mite (HDM) for 8 h twice
over 48h. Increases in transporter expression were measured following each treatment, with
the protein levels of the OCTN2 subtype consistently raised by at least 50%. Interestingly, OCT
upregulation upon LPS and HDM challenges were dependent on an inflammatory event
occurring in the cell layers. Salbutamol permeability was higher in LPS exposed layers than in
their untreated counterparts and in both cases, was sensitive to the OCT inhibitor
tetraethylammonium. This study is the first to show epithelial injury, inflammation and allergen
abuse upregulate OCT in bronchial epithelial cells, which might have an impact on the
absorption of their substrates in diseased lungs.
Keywords
airway epithelium; drug transporters; permeability; inflammation; in vitro model
3Abbreviations
ALI: air-liquid interface; AMC: 7-amino-4- methylcoumarin; BSA: bovine serum albumin;
CCL17: chemokine (C-C motif) ligand 17; CCR3: C-C chemokine receptor 3; COX-2:
cyclo-oxygenase 2; EDTA: ethylenediaminetetraacetic acid; HBSS: Hank’s Balanced Salt
Solution; HDM: house dust mite; HPLC-MS/MS: high performance liquid chromatography-
tandem mass spectrometry; ICW: In-Cell WesternTM; LPS: lipopolysaccharide; LY: lucifer
yellow VS dilithium salt; OCT: Organic Cation Transporters; Papp: Coefficient of apparent
permeability; PAR-2: protease activated receptor-2; qPCR: quantitative polymerase chain
reaction; TARC: thymus and activation regulated chemokine; TEA: tetraethylammonium;
TEER: trans-epithelial electrical resistance.
41. Introduction
Inhaled bronchodilators of the β2-adrenoceptor agonist and M3 muscarinic receptor antagonist
classes are routinely used in the management of asthma and chronic obstructive pulmonary
disease. In order to exert their pharmacological activity on the airway smooth muscles, the
drugs need to overcome the physical barrier provided by the lung epithelium. However, they
bear a net positive charge at physiological pH; hence, are expected to exhibit an intrinsic low
permeability across biological membranes, which thus places a question mark over the
mechanism by which they cross the epithelium.
In vitro data suggests that carrier proteins, particularly those within the Organic Cation
Transporter family (OCT), might facilitate their pulmonary absorption (Bosquillon, 2010;
Nickel et al, 2016; Salomon and Ehrhardt, 2012). OCTs are members of the super family of
solute-link carriers SLC22A and comprise the electrogenic OCT1 (SLC22A1), OCT2
(SLC22A2), OCT3 (SLC22A3) sub-types as well as the pH-dependent OCTN1 (SLC22A4)
and OCTN2 (SLC22A5) transporters (Koepsell et al, 2007). It is now well established that
inhaled bronchodilators have the capacity to inhibit OCT proteins (Bosquillon, 2010;
Mukherjee et al, 2012; Salomon et al, 2015) and can be transported by them. The M3
antagonists ipratropium and tiotropium are indeed substrates for OCT1, OCT2, (Hendrickx et
al, 2013; Nakanishi et al, 2011) as well as OCTN2 (Nakamura et al, 2010); OCT3 transports
only the former (Hendrickx et al, 2013) and OCTN1 has a low affinity for both compounds
(Nakamura et al, 2010). Data are less comprehensive regarding the β2 agonists but nevertheless
indicate salbutamol is transported by OCT1 (Salomon et al, 2015) and possibly OCTN2 (Gnadt
et al, 2012). In addition, formoterol is likely a substrate for at least one member of the
transporter family since its uptake by airway smooth muscles was reduced in presence of OCT
inhibitors (Horvath et al, 2007).
5Evidence for an OCT-mediated absorption across the airway epithelium is currently limited to
salbutamol. The drug was transported to a higher extent in the absorptive than the secretory
direction in differentiated epithelial layers of the human bronchial cell lines 16HBE14o- and
Calu-3 (Ehrhardt et al, 2005) or the bronchiolar cell line NCI-H441 (Salomon et al, 2015).
Moreover, OCT inhibitors reduced the drug absorption in the three cell-culture models when
added to the transport medium (Ehrhardt et al, 2005; Haghi et al, 2012; Mamlouk et al, 2013;
Salomon et al, 2015). Conversely, a study in normal human bronchial epithelial cell layers
concluded that passive diffusion was the primary mechanism for salbutamol transport (Unwalla
et al, 2012). Permeability values in the cell layers were nevertheless two orders of magnitude
greater, both for salbutamol and the paracellular marker mannitol, than those reported in the
cell lines (Ehrhardt et al, 2005; Mamlouk et al, 2013; Salomon et al, 2015). The impact of
transporters might therefore have been concealed in such permeable layers.
Transepithelial permeability data for salbutamol have so far been collected in cell layers
representing a healthy epithelium. However, in a clinical setting, the drug is most commonly
administered to asthmatic lungs. Those are characterised by chronic inflammation, often
consecutively to a disproportionate reaction of the pulmonary tissue to inhaled environmental
agents. In addition, they exhibit areas of scarring due to defective repair mechanisms following
repetitive injury of a hypersensitive epithelium (Holgate, 2011). Epithelial inflammation and
wounding might alter OCT expression profile in the lung epithelium, as reported in other
tissues. For instance, OCT2 was shown to be downregulated in rat kidneys following injury (Ji
et al, 2002) while the renal expression of both OCT1 and OCT2 was decreased upon tissue
inflammation induced by administration of the pro-inflammatory agent lipopolysaccharide
(LPS) (Heemskerk et al, 2008). In contrast, OCTN1 and OCTN2 levels were raised in rat liver
during tissue regeneration post partial resection (Dransfeld et al, 2005). A similar increase in
the expression of the latter transporter was also observed in inflamed sections of the intestine
6in humans (Fujiya et al, 2011). More significantly, as of direct relevance to asthma, variations
in OCT1-3 pulmonary expression were measured in rat and murine lungs following their
exposure to the model allergen ovalbumin (Lips et al, 2007).
Since inhaled bronchodilators essentially face an inflamed and wounded epithelium when
administered to patients, the aim of this study was to evaluate the effect of epithelial insults
relevant to asthma on OCT expression in Calu-3 bronchoepithelial cell layers and
consequences on salbutamol transepithelial transport. Calu-3 layers maintained at an air-liquid
interface (ALI) provide an in vitro model anatomically close to the native bronchial epithelium
(Grainger et al, 2006). Importantly, they have been shown to express the same OCT subtypes
as normal human bronchial epithelial cell layers (OCT1, OCT3, OCTN1 and OCTN2) on their
apical side (Mukherjee et al, 2012) and were deemed a reliable cell culture system for asthma
research (Stewart et al, 2012).
ALI Calu-3 layers were physically injured or exposed to environmental agents relevant to
asthma, i.e., LPS, a component of Gram negative bacteria wall present in organic dusts and
well known to cause lung inflammation (Thorn, 2001) and the aeroallergen house dust mite
(HDM), a major trigger for allergic asthma (Gandhi et al, 2013). Changes in OCT expression
resulting from the insults were quantified at the gene and protein level by quantitative
polymerase chain reaction (qPCR) or In-Cell WesternTM (ICW), respectively. Salbutamol
absorptive transport was then measured in LPS challenged and control layers in presence of an
OCT inhibitor in order to investigate whether the drug is differentially handled by a healthy or
an inflamed epithelium.
72. Materials and methods
2.2. Materials
Calu-3 cells were obtained from the American Type Culture Collection (ATCC, Rockville,
MD, USA). LPS from E. coli 0:111B4 was purchased from Sigma-Aldrich (Dorset, UK) and
HDM extracts from Indoor Biotechnologies (Warminster, UK). Primers for qPCR analysis
were designed using a Beacon Designer Version 7.0 and obtained from Invitrogen, UK (Table
1). The rabbit primary antibodies used for OCT detection by ICW were from Alpha Diagnostics
and the anti-GAPDH primary antibody raised in mouse from Sigma-Aldrich. The
corresponding secondary antibodies goat anti-rabbit IgG (IRDye® 800CW Conjugate) and goat
anti-mouse IgG (IRDye® 680CW Conjugate) were from LI-COR Biosciences UK Ltd
(Cambridge, UK). Salbutamol sulfate was purchased from Alfa Aesar (Heysham, UK). Cell
culture media and reagents as well as all other chemicals were from Sigma-Aldrich.
2.3. Characterisation of HDM extracts
The dry HDM extracts were reconstituted in Phosphate Buffer Saline (PBS) and stirred
overnight at 4ºC. The preparation was centrifuged at 13,000 rpm for 20 min and the collected
supernatant stored at -20°C. The total protein content was estimated using the method
developed by Lowry. One mL of Lowry AB solution consisting of 20 ml of 2% sodium
carbonate, 100 µL NaK tartrate and 100 µL 1% copper sulphate was added to 0.9 mL of the
reconstituted extracts or bovine serum albumin (BSA) standards. After 10 min incubation at
room temperature, 100 µL of 1:1 Folin reagent in dH2O was added and each solution vortexed.
200 µL of each sample was transferred in triplicate into a clear 96-well plate. Samples were
read at 750 nm using a Dynex Technologies MRX II plate reader running the Dynex Revelation
version 4.02 software. A protein content equivalent to 13.5 µg/µL was obtained after
dissolution of 2.2 grams of dry extracts in 14 mL of PBS.
8The fluorogenic substrate Boc-Gln-Ala-Arg-AMC was used to measure the activity of the
cysteine protease Der p1. 20 µL of HDM preparation was reacted with 180 µL of PBS pre-
warmed at 37°C containing 5 mM cysteine and 0.9 µL/mL of Boc-Gln-Ala-Arg-AMC (10 mM)
in a black 96-well plate in triplicate. The fluorescence of 7-amino-4- methylcoumarin (AMC)
released from the substrate was measured using a DYNEX Microtiter Plate MFX Revelation
Fluorometer equipped with the Dynex Revelation v4.21 software at t = 0, 10 and 20 min.
Relative fluorescence units were converted into picomoles using a standard curve obtained with
increasing concentrations of free AMC. The specific Der p1 activity of the HDM extracts was
calculated as 345 picomoles degraded/mg/min.
2.4. Cell culture and maintenance
Calu-3 cells were cultured in the same conditions as reported by Grainger et al [21]. Briefly,
they were maintained in Dulbecco’s modified Eagle’s medium nutrient mixture F-12 Ham
supplemented with 10% foetal bovine serum (non USA origin, sterile filtered) , 100 UI/mL
penicillin and 100 µg/mL streptomycin, 20 mM L-glutamine and 1% non-essential amino acids
at 37°C in a humidified 5% CO2 atmosphere. When approximately 90% confluence was
reached, they were passaged using 0.25% trypsin/0.1% ethylenediaminetetraacetic acid
(EDTA) and seeded at a density of 105 cells/cm2 onto 0.4 µm pore size, 1.13 cm2 surface area
polyester Transwell® cell culture inserts (Co-Star Corning, Corning, UK) with 0.5 and 1.5 mL
of cell culture medium in the apical or basolateral chamber, respectively. After 24 hours, cells
were raised at an ALI by removing medium from the apical chamber and lowering the volume
of basolateral medium to 0.5 mL. For quantification of OCT protein expression by ICW, cells
were grown on the reverse side of the Transwell® membrane as described previously
(Mukherjee et al, 2013) and ALI conditions were created by feeding the cells from the apical
chamber. The medium was replaced every 2-3 days for up to 21 days when cell layers were
used for experimentation. The integrity of the layers was assessed by measuring the trans-
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electrodes (World Precision Instruments, Stevenage, UK) and only cell layers with TEER
values above 400 Ω.cm2 were included in the study. Cells were used at passage 27 to 39 and
cells from the same passage were treated in parallel for quantification of OCT expression at
the gene or protein level.
2.5. Physical injury
Nineteen day old Calu-3 layers were mechanically scraped using a sterile 10 µL pipette tip to
form three homogenous and parallel scratches. After scraping, the wells were washed with
media and the TEER was measured. The layers were then maintained in supplemented cell
culture medium under submerged conditions and their healing was monitored via TEER
measurements and time-lapse microscopy. Immediately after wounding of the layers, the
Transwell® plate was transferred to the built-in chamber of a Leica DR IRBE microscope which
provided a humidified CO2 atmosphere at 37°C. Images of the scratches were captured by an
ORCA-285 1394 high resolution digital camera (Hamamatsu, Japan) every 30 min over 48
hours. OCT expression was measured in the healed layers 48 h after injury by qPCR and ICW.
2.6. LPS and HDM challenges
Nineteen day old Calu-3 layers were exposed to 10 µg/mL LPS on their apical side in presence
or absence of 1 µM of the anti-inflammatory steroid hydrocortisone in 500 μL of cell culture 
medium while 1.5 mL of medium was added to the basolateral compartment. TEER
measurements were taken at regular time intervals over 48h before cells were harvested for
quantifying mRNA levels of the OCT and inflammatory markers, or the cell layers were
processed for ICW analysis.
For the allergen challenge, solutions of reconstituted HDM extracts were prepared at various
protein concentrations in serum-free cell culture medium supplemented with 1 mM cysteine in
order to maintain Der p1 activity. The presence of serum in the medium, even when heat
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inactivated, indeed resulted in a loss of the allergen enzymatic activity (data not shown).
Nineteen day old Calu-3 layers were exposed to 500 μL of the HDM preparations on their 
apical side for 8 h, an exposure time that allowed the detection of the chemokine CCL17
released in the cell culture medium (data not shown). During HDM exposure, cells were
maintained in serum-free conditions but then were allowed to recover at an ALI in full culture
medium. The TEER was regularly measured over a 48 h period spanning the exposure and
recovery phases. Subsequently, the layers were subjected to two similar 8 h long exposures to
HDM at a total protein concentration of either 2.0 or 3.0 µg/µL, each followed by a 16 h
recovery phase. Cells were collected at t = 0, 8, 24, 32 and 48 h for assessing the mRNA levels
of the OCT and inflammatory markers. OCT protein expression was quantified at the end of
the second recovery period.
2.7. Quantification of gene expression
Changes in gene expression upon cell treatment were measured by qPCR following the MIQE
guidelines (Bustin et al, 2009). Calu-3 layers were rinsed with ice cold PBS and harvested from
the Transwell® using non-enzymatic cell dissociation buffer. cDNA was synthesised using a
µMacs RNA extraction and cDNA synthesis kit (Miltenyi Biotech, UK) according to the
manufacturer’s instructions. Nucleic acid quantity and purity were assessed using a Nanodrop
ND-1000 spectrophotometer (Thermo Scientific, USA). The Brilliant Sybr Green qPCR
Master Mix (Stratagene, La Jolla, CA, USA) was used for the amplification reactions. The
reaction mixture was made of 12.5 µl of Sybr Green Mix, 1 µl of primer mix (forward and
reverse, 5 µM), 0.5-1.0 µl of cDNA template and DEPC-treated water up to 25 µl. The cycling
conditions included 15 min polymerase activation at 95°C, and 40 cycles at 95°C for 15 s,
55/60°C for 30 s, and at 72°C for 30 s. Reactions were run on an Mx3005P (Stratagene) Real-
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Time PCR Detection System according to the manufacturer’s protocol (Software: MxPro-
Mx3005P v4.01 (c) 2007, Stratagene). The primers were designed using Beacon Designer
Version 7.0 and validated on a gradient using untreated Calu-3 cDNA in order to determine the
annealing temperature. The melt curves were generated and the amplification efficiency of each
primer was determined for each gene by serial dilutions of the basal Calu-3 cDNA. Two
reference genes, i.e., 18S and GAPDH were assessed for normalising expression of the genes
of interest between cell layers. Minimum variation of the Ct value was observed between
samples for GAPDH. Therefore, relative gene expression levels were calculated by the ΔΔCt 
method as followed:
Efficiency (gene of interest) ^ (Ct basal control – Ct treatment)
Gene expression = ---------------------------------------------------------------------
Efficiency(GAPDH) ^ (Ct basal control – Ct treatment)
2.8. Quantification of protein expression
Variations in OCT protein levels induced by the different challenges were quantified in intact
cell layers by In-Cell WesternTM (ICW) according to a protocol previously validated
(Mukherjee et al, 2013). Briefly, Calu-3 layers were washed with ice cold PBS, fixed with 4%
paraformaldehyde, permeabilised with PBS containing 1% BSA and finally blocked with 1:25
human serum in PBS. A solution containing the primary antibody against the OCT subtype of
interest (raised in rabbits) as well as the primary antibody against GAPDH (raised in mice) was
prepared in PBS containing 0.1% BSA to achieve 1:1000 dilutions of the antibodies. This,
together with the blocking serum, was added as a 100 µL droplet on top of the cell layers. After
an overnight incubation at 4°C, the layers were washed with 0.1% BSA and 0.05% Tween in
PBS. They were then exposed to 100 µL of 1:1000 dilutions of the secondary antibodies in
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PBS containing 0.1% BSA before a rigorous wash with PBS supplemented with 0.1%BSA and
0.05% Tween followed by a quick wash with Millipore grade water on a Stuart® SSM1orbital
shaker at 50 rpm (Bibby Scientific Limited, Staffordshire, UK).
Each individual Transwell® insert was scanned using the LI-COR Odyssey® NIR Imaging
system (LI-COR Biosciences, Cambridge, UK) in order to detect the two simultaneous IRDye®
signals (green for OCT and red for GAPDH). These were then quantified by the LI-COR
Odyssey® Software V3.0 (LI-COR Biosciences).
The red intensity corresponding to GAPDH expression was used to normalise variations in cell
number between the different wells. The background signal was obtained by treating Calu-3
layers with the anti-GAPDH primary antibody followed by both secondary antibodies. OCT
protein levels were quantified based on the ratio of the green to the red intensity within the
same well. Protein expression in treated layers was expressed as a percentage increase from
basal expression in control layers.
2.9. Transepithelial transport of salbutamol after LPS challenge
The permeability of salbutamol sulfate was measured in the presence or not of the OCT
inhibitor tetraethylammonium (TEA) in Calu-3 layers after LPS challenge and in control layers
for comparison.
At day 19 after seeding on the Transwells®, cell layers were exposed to 10 µg/mL LPS as
described above or covered with the same volume of medium.
After 48 h, the layers were washed once with 0.5 mL of pre-warmed PBS, and moved to clean
12-well plates. They were then equilibrated in Hank’s Balanced Salt Solution (HBSS) at 37°C
for 30 min before the TEER was recorded. 200 μL of 5.0 μg/mL solution of salbutamol in pre-
warmed HBSS ± 5 mM TEA was placed in the apical chamber of the Transwells® and 900 μL 
of HBSS ± 5 mM TEA at 37°C was added to the basolateral chamber. Cell layers were placed
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on an orbital shaker (60 rpm) inside the incubator. 200 μL samples were withdrawn from the 
basolateral compartments at different time points over 4 h and replaced with the same volume
of corresponding buffer. Directly after collection of the last sample, the final TEER was
measured and the permeability of the paracellular marker lucifer yellow VS dilithium salt (LY)
across the layers was quantified. Briefly, 300 μL of 100 μM LY solution in pre-warmed HBSS 
was placed in the apical chamber while 900 µL of the buffer was added to the basolateral
chamber. 100 μL were sampled from the basolateral chamber after 30 and 60 minutes and 
transferred to a black 96 well-plate (Nunc F96, Scientific Laboratory Supplies, Nottingham,
UK). The fluorescence was assayed using a Tecan (SPARK 10M) plate-reader at λem= 437 nm
and λex= 535 nm.
During both salbutamol and LY permeability measurements, samples (100 µL) were taken
from the apical side at the beginning and at the end of the experiment for determination of the
mass balance.
Salbutamol transport data were accepted if the TEER remained above 400 Ω.cm2, the LY
flux was less than 2.0% over 60 minutes and the mass balance was in the 75-110% range.
The coefficient of apparent permeability (Papp) was calculated according to the following
equation:
0
/
AC
dtdQPapp 
where dQ/dt (mol. s-1) is the transport rate, A (cm2) is the surface area of the filter supporting
the cell layer, and C0 (mol. cm-3) is the initial substrate concentration in the donor chamber.
2.10. Salbutamol analysis
Salbutamol sulfate was quantified by high performance liquid chromatography-tandem mass
spectrometry (HPLC-MS/MS). The HPLC system consisted in an Agilent Hewlett Packard
14
series 1100 coupled with a Micromass Quattro Ultima Pt mass spectrometer (Waters, Milford,
USA) equipped with an electrospray ion source operated in positive mode. An ACE3 C18 (3
μm, 150 mm x i.d. 2.1 mm) column fitted with a C18 guard cartridge was used for all analysis.  
Salbutamol sulfate samples were diluted 1:1 with methanol (HPLC grade), vortexed for 1 min
and centrifuged at 5,000 rpm for 5 min at 4°C. The supernatant was diluted 1:1 with phase A
consisting of an aqueous solution containing 0.1% v/v formic acid, ammonium formate 20 mM
(pH 3.8), and 50 µL of the resulting solution was injected in the HPLC-MS/MS system for
quantification. Samples were run isocratically at 0.2 mL min-1 using a mixture of phase A and
MeOH (50:50) as the mobile phase. Salbutamol was detected in multi reaction monitoring
(MRM) mode at m/z 240.1  148.1. MS parameters were as follows: capillary voltage, 3.5
kV; cone voltage, 35 V; source temperature, 125°C; desolvation temperature, 350°C; collision
energy, 20 kV.
2.11. Statistical analysis
All experiments were conducted on 3-4 layers over at least two different passages. Data are
presented as the mean ± standard error of the mean (SEM). A Student t-test was performed for
comparing two groups while ANOVA followed by post-hoc tests (Bonferroni’s or Tukey’s for
expression or transport data, respectively) was used for comparing more than two groups. A p
value < 0.05 was considered to be statistically significant. Graphpad prism software version
6.02 was used for statistical analysis of the data.
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3. Results
3.1. Increased OCT expression following recovery from a scrape wound
Calu-3 layers were mechanically scraped in order to mimic epithelial injury and scarring
observed in asthma. Immediately after inflicting the scratches, the TEER dropped to ~ 150
Ω.cm2 for all experimental wells but returned to values above 600 Ω.cm2 after 48 h (data not
shown). The formation of a physical wound and its repair within 48 h was evident from time-
lapse microscopy images (Figure 1).
A significant increase in the mRNA levels of OCT1, OCT3 and OCTN2 was observed in healed
layers when compared to basal levels in their unwounded counterparts (Figure 2A). OCT1 and
OCTN2 protein expression in broncho-epithelial cells was concomitantly raised by more than
50% after recovery from the injury while only a marginal increase in expression was observed
for OCT3 and OCTN1 (Figure 2B)
3.2. Increase OCT expression upon LPS challenge
Cell layers were treated with LPS primarily to induce an inflammatory reaction and thus, mimic
the condition of an asthmatic epithelium. Exposure of Calu-3 layers to LPS from E. coli
0:111B4 over 48 h did not affect their physical integrity as assessed via regular TEER
measurements (data not shown). Nevertheless, a significant up-regulation of the inflammatory
markers cyclo-oxygenase 2 (COX-2), chemokine (C-C motif) ligand 17 (CCL17) - also called
thymus and activation regulated chemokine (TARC) - and C-C chemokine receptor 3 (CCR3)
was observed in treated cells (Figure 3A), which indicated that LPS was able to trigger an
inflammatory event in Calu-3 cell layers. This was associated with fold increases in OCT1,
OCT3 and OCTN2 gene expression (Figure 3A) as well as an enhancement of protein levels
by approximately 20% for OCT1 or 50% for OCTN1 and OCTN2 (Figure 3B).
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As expected, the presence of hydrocortisone in the test medium curbed the LPS-induced
inflammatory cascade, as evidenced by COX-2, CCR3, and CCL17/TARC remaining at basal
levels in cell layers exposed to both compounds simultaneously (Figure 3A). Interestingly, in
these conditions, LPS impact on OCT expression was also abolished (Figure 3A), suggesting
upregulation of the transporters was driven by epithelial inflammation.
3.3. Increased OCT expression following HDM challenge
As asthma is known to very commonly have an allergic component, cell layers were also
challenged with the widespread airborne allergen HDM. Cell layers were initially treated with
various concentrations of reconstituted HDM extracts for 8 h in order to monitor their effects
on epithelial tight junctions. It had indeed previously been shown that HDM proteases have the
capacity to cleave tight junction proteins (Gandhi et al, 2013). Protein concentrations above 3
µg/µL irreversibly damaged the cell layers while a concentration of 3 µg/µL disrupted these to
an extent where the TEER dropped below 400 Ω.cm2 but reformation of functional tight
junctions occurred within 48 h (Figure 4). Finally, even though 2 µg/µL HDM proteins caused
a statistically significant reduction in TEER after 8 h exposure (Figure 4), the absolute TEER
values remained above 400 Ω.cm2, indicating that the barrier properties of the cell layers were
mainly preserved.
Based on those preliminary results, layers were then challenged with the allergen at a disruptive
but non-lethal dose of 3 µg/µL as well as the highest safe dose of 2 µg/µL twice, over the total
time span of 48h with a 16 h recovery period following each challenge in order to mimic a
daily inhalation of the allergen. Although cell layers exposed to the highest concentration were
unable to fully restore their barrier properties between the two challenges, this experimental
set up provided an in vitro model exhibiting defective tight junctions, as observed in the
bronchial epithelium of asthmatic patients (Xiao et al, 2011).
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In an event where the Calu-3 tight junctions were reversibly disrupted, mRNA levels of all
OCT as well as the inflammatory markers COX-2, CCR3, CCL17/TARC and protease
activated receptor-2 (PAR-2) were raised at the end of the first 8h HDM exposure. They
nevertheless returned to basal levels within 24h (Figure 5A). Interestingly, the second HDM
exposure led to lower fold increases in the expression of the OCTs, COX-2, CCR3 and
CCL17/TARC genes than the initial treatment (Figure 5A). Furthermore, expression remained
elevated during the subsequent recovery period (Figure 5A) despite TEER values returning to
their initial values (data not shown). At the end of this second recovery period, the OCT1 and
OCT3 protein levels were slightly increased while those of OCTN2 were raised by around 60%
(Figure 6).
In contrast, when the HDM challenge did not affect tight junction functions, it failed to induce
an inflammatory reaction in the epithelial layers. In that case, no change in the expression of
inflammatory markers was indeed noticed (Figure 5B). Quite strikingly, only the OCTN2 gene
was actually overexpressed and showed sustained high mRNA levels over the course of the
experiment (Figure 5B). Expression of the other OCTs was unmodified, indicating that their
upregulation by HDM was conditional to the development of an inflammatory reaction in the
layers likely triggered by the loss of their barrier function. It is however noteworthy that the
fold increase in OCTN2 mRNA levels was significantly higher after exposure to the tight
junction disruptive concentration of the allergen than to the lower milder concentration (20.3
± 2.2 vs. 10.1 ± 3.8, p < 0.001). This suggests that inflammation also played a role in the
upregulation of the gene but this had nevertheless the capacity to respond to an allergen
independently of epithelial damage or the inflammation cascade.
3.4. Increased salbutamol transport after LPS challenge
How enhanced OCT expression in inflamed Calu-3 layers impacts on salbutamol permeability
was assessed following cell exposure to LPS for 48 h since this treatment caused upregulation
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of the OCT1, OCTN1 and OCTN2 proteins, without affecting the TEER or epithelial
morphology.
Salbutamol Papp in control cell layers (Table 2) was slightly lower than in other studies
(Ehrhardt et al, 2005; Haghi et al, 2012) in which the drug permeability was measured at a
much higher concentration across 10-14 day old Calu-3 layers. However, as previously
reported (Ehrhardt et al, 2005; Haghi et al, 2012, Mamlouk et al, 2013), the drug transepithelial
transport was reduced when the layers were exposed to TEA (Figure 7), thus confirming an
OCT involvement.
Despite similar TEER and LY flux between all cell layers, salbutamol permeability was more
than doubled in LPS challenged layers as compared to non-treated layers and importantly, was
still sensitive to TEA (Table 2, Figure 7). This indicated that the increase in salbutamol
transport following LPS exposure was not promoted by enhanced passive diffusion but more
likely by the inflammation driven overexpression of the OCT.
4. Discussion
In vitro transport data in airway epithelial cell layers suggest that the pulmonary absorption of
salbutamol, and possibly other cationic inhaled bronchodilators, might be facilitated by the
OCT family of transmembrane carriers. Those data have nevertheless been obtained in models
of a ‘healthy’ epithelium while, in a clinical setting, the drugs have to cross an inflamed and
remodelled epithelium that might exhibit a different OCT expression pattern. The impact of
epithelial injury, inflammation and allergen exposure on OCT broncho-epithelial levels was
therefore investigated in Calu-3 ALI layers. Salbutamol permeability was subsequently
compared in inflamed and healthy layers. All three epithelial insults were shown to upregulate
OCT, with variable effects on the different subtypes. Furthermore, inflammation enhanced
salbutamol transepithelial transport, most likely via increased OCT expression.
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Upregulation of the different OCT sub-types upon cell treatment did not follow similar trends
when assessed by qPCR or ICW. This is not an unusual observation since poor correlations are
commonly found between mRNA and protein levels because of post-transcriptional regulation
and/or degradation of proteins (Vogel and Marcotte, 2012). Nevertheless, epithelial
inflammation was found to be a major factor in the enhanced expression of the transporters
post LPS and HDM challenges. Epithelial injury caused similar fold increases in OCT levels
although it is unclear whether this was promoted by cell proliferation or linked to a possible
post-wounding inflammatory reaction. Expression data in Calu-3 layers were in agreement
with previous studies which had reported changes in OCT levels following an inhaled allergen
challenge (Lips et al, 2007), kidney (Ji et al, 2002) or liver (Dransfeld et al, 2005) resection
and in inflamed renal (Heemskerk et al, 2008) and intestinal (Fujiya et al, 2011) tissues.
However, this study is the first to show both allergic and non-allergic inflammations together
with physical injury regulate OCT in epithelial cells through direct stimulation, i.e., without
the involvement of other cell types, particularly of the immune system.
The development of an inflammatory reaction in the Calu-3 cell layers was confirmed by the
increased expression of COX-2, CCL17/TARC and CCR3, as well as PAR-2 during the HDM
challenge. COX-2 is an ubiquitously expressed enzyme responsible for the synthesis of
prostaglandins and is induced at inflammation sites (Dubois et al, 1998). It was therefore used
as a general inflammatory marker in this study. CCL17/TARC and CCR3 are both
overexpressed in airway epithelial cells in vitro following exposure to pro-inflammatory
stimulants (Heijink et al, 2007; Stellato et al, 2001) but also, in the airways of asthmatic patients
(Beck et al, 2006; Sekiya et al, 2002). Their upregulation in Calu-3 cell layers upon stimulation
by LPS and HDM therefore indicated that the inflammatory event orchestrated in the cell line
was relevant to asthma.
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Both LPS and HDM are known to activate the transcription factor NFκB following their 
recognition by Toll-like receptors (principally TLR-4) or protease-activated receptors
(principally PAR-2) respectively, located at the surface of airway epithelial cells, which then
stimulates the synthesis and release of various cytokines and chemokines (Gandhi et al, 2013;
Chen et al, 2011). OCT genes appear therefore under the control of the NFκB pathway in the 
bronchial epithelium.
Although both environmental agents increased OCT expression as part of the inflammation
cascade, the inflammatory reaction triggered by LPS was independent of tight junction
disruption whereas it was associated with a loss of barrier function in case of HDM exposure.
It has previously been shown that the proteolytic components of the HDM extracts could cleave
tight junction proteins in vitro but also that PAR-2 activation by the allergen led to a decrease
in the adhesion properties of the tight junction protein E-cadherin (Gandhi et al, 2013). Tight
junction disruption by the calcium chelating compound EDTA did not modify OCT levels in
Calu-3 layers (data not shown), suggesting that inflammation was the only process behind OCT
upregulation by HDM.
The OCTN2 subtype was nevertheless an exception since its expression was enhanced in a
HDM challenge even in absence of an inflammatory reaction. Expression of the transporter
was, in addition, the most largely increased amongst OCT subtypes during epithelial non-
allergic inflammation or post recovery from a wound. Interestingly, single nucleotide
polymorphisms (SNPs) in the OCTN2 gene have been associated with an increased
susceptibility to develop asthma (Moffatt et al, 2010). The transporter carries the endogenous
antioxydant L-carnitine (Koepsell et al, 2007) and was upregulated in Calu-3 cells after
treatment with rosiglitazone, an agonist of the nuclear receptor Peroxisome Proliferator-
Activated Receptor  (PPAR) (Mukherjee et al, 2013). PPAR is a ligand-activated
transcription factor which is known to control immunity and inflammation and is being
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explored as a potential pharmacological target in asthma (Park and Lee, 2008). This suggests
that OCTN2 might participate in anti-inflammatory and/or anti-allergic events in bronchial
epithelial cells until those are overridden by pro-inflammatory processes.
Overexpression of the OCT1, OCTN1 and OCTN2 proteins in LPS challenged Calu-3 layers
resulted in a two-fold increase in salbutamol transport as compared to that in untreated cells.
The drug transport in both inflamed and control layers was reduced in presence of the OCT
inhibitor TEA, indicating it was partly mediated by at least one member of the transporter
family. While the drug has been shown to be a substrate for OCT1 (Salomon et al, 2015), only
indirect evidence suggests it might also be transported by OCTN2 Gnadt et al, 2012). On the
other hand, its interactions with OCTN1 have not been investigated to date. Considering LPS
raised OCT1 levels by only ~ 20%, upregulation of this transporter alone cannot be accounted
for the increase in salbutamol permeability across the inflamed layers. The OCTN1 and/or
OCTN2 protein(s) whose expression was enhanced by around 50% upon LPS exposure are
therefore likely to contribute to the drug active transport in the Calu-3 model.
Although the inflammation reaction induced in the cell line following LPS or HDM exposure
was representative of epithelial inflammation in asthma, it is unknown whether broncho-
epithelial cells from asthmatic patients actually respond to pro-inflammatory stimulants by
upregulating the OCTs and thus, differentially express the transporters as compared to healthy
cells. Until such data are available, the clinical significance of the enhancement in OCT
expression and salbutamol absorption observed in Calu-3 layers during an inflammatory event
will remain speculative. Our work nevertheless suggests that common features of asthma such
as epithelial injury and inflammation, both of allergic and non-allergic origin, have the potential
to alter transporter expression in the pulmonary epithelium with possible consequences on the
fate of their substrates in diseased lungs.
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5. Conclusions
This study showed that epithelial insults relevant to asthma have the capacity to upregulate
OCTs in bronchial epithelial cell layers in vitro without the participation of other cell types,
such as immune cells. It also demonstrated that an inflammatory event in the layers enhanced
the transepithelial permeability of the bronchodilator salbutamol via OCT overexpression. The
clinical significance of these findings remains nevertheless to be determined. Quantifying OCT
expression in asthmatic vs. healthy bronchial epithelial cells would, for instance, be particularly
informative.
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Figure legends
Fig 1: Time lapse microscopy images showing the healing within 48 h of a scrape wound
inflicted to air-liquid interfaced Calu-3 layers. The scale bar represents 250 µm.
Fig 2: Variation in Organic Cation Transporter (OCT) expression profile in Calu-3 air-liquid
interfaced layers following recovery from a scrape wound. (A) fold increases in OCT mRNA
levels. (B) percentage increases in OCT protein levels. *, **, *** indicate statistically
significant increases from basal expression at p < 0.05, p < 0.001, p < 0.0001, respectively.
Fig 3: Variation in Organic Cation Transporter (OCT) expression profile in Calu-3 air-liquid
interfaced layers following exposure to lipopolysaccharide (LPS) for 48h. (A) fold increases in
the mRNA levels of OCT and inflammatory markers. Cell layers were exposed to LPS alone,
LPS and the anti-inflammatory drug hydrocortisone or the drug alone (B) percentage increases
in OCT protein levels in layers exposed to LPS alone. * indicates statistically significant
increases from basal expression at p < 0.05.
Fig 4: Effect of house dust mite (HDM) exposure on the integrity of Calu-3 air-liquid interfaced
layers. Layers were exposed to different HDM protein concentrations for 8 h and the
transepithelial electrical resistance (TEER) was monitored over 48h from t = 0h. * indicates a
statistically significant difference in the TEER value as compared to the initial TEER at t = 0 h
(p < 0.05).
Fig 5: Variations in the mRNA levels of Organic Cation Transporters (OCT) and inflammatory
markers upon exposure of air-liquid interfaced Calu-3 layers to house dust mite (HDM) at a
protein concentration of (A) 3.0 µg/µl, i.e., causing a reversible drop of the TEER below 400
Ω.cm2 or (B) 2.0 µg/µl, i.e., maintaining the TEER above 400 Ω.cm2. Layers were exposed to
HDM for 8 h twice over 48h with a 16h recovery period between each exposure. * indicates
statistically significant increases from basal expression (p < 0.05); # indicates statistically
significant higher levels than at other time points (p < 0.05).
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Fig 6: Variations in Organic Cation Transporter (OCT) protein expression in Calu-3 air-liquid
interfaced layers after two 8h exposure to house dust mite (HDM) at a protein concentration of
3.0 µg/µl followed each by a 16h recovery period. * or ** indicate statistically significant
increases from basal expression at p < 0.05 or p < 0.001, respectively.
Fig 7: Salbutamol apical to basolateral cumulative transport in untreated Calu-3 layers or layers
exposed to lipopolysaccharide (LPS) for 48h in presence or absence of the Organic Cation
Transporter (OCT) inhibitor tetraethylammonium (TEA). * indicates a statistically significant
increase from transport in untreated cells at p < 0.05; # indicates a statistically significant
decrease from transport in absence of TEA at p < 0.05.
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Table 1: details of primers used for qPCR
Protein
(Gene )
Forward and Reverse sequences Tm Annealing
temp. (°C)
Efficiency
(E value)
Size
(bp)
GAPDH F: 5’-ACAGTCAGCCGCATCTTC-3’
R: 3’-GCCCAATACGACCAAATCC-5’
53.8/53.1 55 1.95 101
18s F: 5’-CATCTGCCGTTGGAACCTGAAG-3’
R: 3’-CTTGCGGTGTTCTTCCTGGCAT-5’
55.9/57.8 55 1.95 130
OCT1
(SLC22A1)
F: 5’- TGAAGGACGCCGAGAACC-3’
R: 3’-AGGAAGAATACAGAGAAGTGAAGG-5’
55.7/55.6 50 1.84 188
OCT3
(SLC22A3)
F: 5’-CCACTCCACCATCGTCAG-3’
R: 3’-ACACCAAGGCAGGATAGC-5’
53.5/53.0 60 1.98 168
OCTN1
(SLC22A4)
F: 5’-TGTCATCACCCGTAGTTG-3’
R: 3’-ACATACCATTGAAGCCATTG-5’
50.3/50.9 50 2.1 156
OCTN2
(SLC22A5)
F: 5’-GCTACATGGTGCTGCCACTGTT-3’
R: 3’-CTGCCTCTTCAAATCGTCCCTG-5’
57.7/55.4 50 2.4 156
TARC
(CCL17)
F: 5’-ACTTCTCCCGGGACTACCT-3’
R: 3’-TCCCTCACTGTGGCTCTTCT-5’
52.9/54.1 58 1.95 111
COX-2 F: 5’-CGGTGAAACTCTGGCTAGACAG-3’
R: 3’-GCAAACCGTAGATGCTCAGGGA-5’
54.9/56.7
60 2.3 156
CCR3 F: 5’-TACTCCCTGGTGTTCACTGTGG-3’
R: 3’-ACGAGGAAGAGCAGGTCCGAA-5’
52.9/54.1 55 1.86 134
iNOS F: 5’-GCTCTACACCTCCAATGTGACC-3’
R: 3’-CTGCCGAGATTTGAGCCTCATG-5’
54.8/55.8 60 1.94 136
PAR-2
(F2RL1)
F: 5’-CTCCTCTCTGTCATCTGGTTCC-3’
R: 3’-TGCACACTGAGGCAGGTCATGA-5’
53.7/58.1 58 1.90 152
Tm : Melting temperature
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Table 2: Coefficient of apparent permeability (Papp) of salbutamol in untreated Calu-3 layers
or layers exposed to lipopolysaccharide (LPS) for 48h.
Papp (10-7 cm/s)
Control layers 4.3 ± 0.6
Control layers + TEA 2.5 ± 0.2
Layers exposed to LPS 10.2 ± 3.0
Layers exposed to LPS + TEA 3.7 ± 1.5
Salbutamol transport was measured in the presence or absence of the Organic Cation Transporter (OCT)
inhibitor tetraethylammonium (TEA)
32
Figure 1, Mukherjee et al
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Figure 2, Mukherjee et al
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Figure 3, Mukherjee et al
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Figure 4, Mukherjee et al
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Figure 5, Mukherjee et al
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Figure 6, Mukherjee et al
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Figure 7, Mukherjee et al
